Diagnostic value of 18F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site
Fabian Wolpert(University of Zurich), Émilie Le Rhun(University of Zurich), Michael Weller(University Hospital of Zurich), Lisa Füreder(Comprehensive Cancer Center Vienna), G. Petyt(Université de Lille), Anna S. Berghoff(Medical University of Vienna), Thomas Frauenfelder(University Hospital Zurich), Patrick Roth(University Hospital of Zurich), Marian C. Neidert(University of St.Gallen), Philipp A. Kaufmann(University of Zurich), Roger Stupp(Northwestern University), Nicolas Reyns(Centre National de la Recherche Scientifique), Nicolaus Andratschke(University Hospital of Zurich), Matthias Preusser(Medical University of Vienna), Luca Regli(University of Zurich), Elisabeth J. Rushing(University Hospital of Zurich), Henning Leske(University Hospital Zurich), Reinhard Dummer(University Hospital of Zurich), Rolf A. Stahel(International Breast Cancer Study Group)
Cited by 26
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k